ARTIC RSV amplicon sequencing reveals global RSV genotype dynamics.
Daniel M Maloney,Goncalo Fernandes,Seema Jasim,Tom Williams,Sarah Namugenyi,Michael Carr,Jennifer R Meyer,Aryan Sharma,Louise Marshal,B Ethan Nunley,Hong Xie,Mateo Carvajal,Henry D Kunerth,Arif Tanmoy,Áine O'Toole,Amelia Weixler,Kelsey R Lanter,Gabrial Gonzalez,Jaydee Sereewit,Rommel Guevara,Stuart Astbury,Padraic M Fanning,Denisse Benítez,Juan Carlos Fernandez,Paúl Cárdenas,Daniel Hare,Alex Greninger,Thomas Williams,Gaia Nebbia,Anthony C Fries,Patrick McClure,Pavitra Roychoudhury,Xiong Wang,Senjuti Saha,Rebecca Dewar,Kate E Templeton,Andrew Rambaut
DOI: https://doi.org/10.1101/2024.08.23.609324
2024-08-26
Abstract:Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections (LTRIs) in young children and adults over 65, contributing significantly to global healthcare burdens. With the recent approval of multiple RSV-targeted pharmacological interventions, there is an increased demand for efficient, high-throughput sequencing methods to monitor RSV genetic diversity and the potential impact of these interventions. Here we introduce two novel amplicon-based sequencing schemes designed for the RSV A and B subtypes, optimized for integration with widespread existing ARTIC sequencing workflows. Here we show that this primers schemes can produce high quality genomes from RSV samples across the globe, with eight laboratories in five countries producing complete genomes on both Nanopore and Illumina sequencing platforms. Furthermore, these results provide a snapshot of circulating diversity of RSV. Phylogenetic analysis suggests only minimal geographic clustering of sequences but highlights distinct lineage dynamics between RSV A and B seen across the 882 samples sequenced for this study. The ability to effectively multiplex these RSV A and B primer schemes, enables streamlined, high-throughput sequencing without prior subtyping. This study represents an advancement in RSV genomics, providing robust tools for global sequencing efforts aimed at tracking RSV evolution and assessing the efficacy of new therapeutic interventions rapidly and at scale.
Genomics